Home » Stocks » PACB

Pacific Biosciences of California, Inc. (PACB)

Stock Price: $24.89 USD 0.53 (2.18%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $24.55 -0.34 (-1.37%) May 7, 7:58 PM
Market Cap 5.02B
Revenue (ttm) 92.29M
Net Income (ttm) -59.29M
Shares Out 198.35M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $24.89
Previous Close $24.36
Change ($) 0.53
Change (%) 2.18%
Day's Open 24.85
Day's Range 24.60 - 26.34
Day's Volume 2,483,080
52-Week Range 3.26 - 53.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MENLO PARK, Calif., May 04, 2021 (GLOBE NEWSWIRE) --  Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences:

4 days ago - GlobeNewsWire

Pacific Biosciences' (PACB) revenues grow in both its segments during the first quarter.

4 days ago - Zacks Investment Research

The company released its first-quarter earnings report, but that doesn't tell the whole story.

1 week ago - The Motley Fool

Shares of Pacific Biosciences (NASDAQ:PACB) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 4600.00% over the past year to ($0.45), which we...

1 week ago - Benzinga

MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2021.

1 week ago - GlobeNewsWire

MENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, announced today that Dr...

1 week ago - GlobeNewsWire

MENLO PARK, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of g...

2 weeks ago - GlobeNewsWire

Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

MENLO PARK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its first quarter 2021 financial results ...

3 weeks ago - GlobeNewsWire

We're really excited that these genomics companies, says Ark's Simon Barnett

YouTube video

Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.

Other stocks mentioned: ADPT, ARKG, NVTA
3 weeks ago - CNBC Television

These two disruptive companies have long growth runways ahead of them.

Other stocks mentioned: NET
1 month ago - The Motley Fool

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

MENLO PARK, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences:

2 months ago - GlobeNewsWire

The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.

Other stocks mentioned: PFE, MRNA
2 months ago - Investors Business Daily

The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.

Other stocks mentioned: AZN, BNTX, GILD, GSK, ILMN, JNJ, LLY ...
2 months ago - Investors Business Daily

Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.

Other stocks mentioned: LH
2 months ago - Zacks Investment Research

The stock price of Pacific Biosciences of California a biotechnology company that develops gene sequencing systems, has seen a solid 27% rise over the last ten trading days, though it's down 4% over the...

2 months ago - Forbes

Labcorp Using PacBio's HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S. Labcorp Using PacBio's HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S.

2 months ago - GlobeNewsWire

Will SoftBank Group Corp.'s (SFTBY) huge investment in Pacific Biosciences of California Inc.(NASDAQ:PACB) turn out to be another home run for the Japanese conglomerate or will it be a swing and a miss ...

2 months ago - GuruFocus

Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.

2 months ago - Zacks Investment Research

ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 for advanced...

Other stocks mentioned: ANAB, EPIX
2 months ago - Benzinga

With the trading day more than halfway over, the broad markets were trading sideways on Thursday.

Other stocks mentioned: CSCO, LYFT, UBER, VMW, CCJ, IRBT, MELI ...
2 months ago - 24/7 Wall Street

The pandemic didn't weigh on the genetic sequencing systems company nearly as much as earlier in 2020.

2 months ago - The Motley Fool

The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.

2 months ago - The Motley Fool

The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.

2 months ago - The Motley Fool

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -102.33% and -0.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Pacific Biosciences (NASDAQ:PACB) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 0.00% over the past year to $0.37, which beat...

2 months ago - Benzinga

MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2020. Re...

2 months ago - GlobeNewsWire

Pacific Biosciences is getting an investment from a holding company.

2 months ago - The Motley Fool

MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”), a leading provider of high-quality, long-read sequencing platforms, today an...

2 months ago - GlobeNewsWire

SoftBank Group Corp (OTCMKTS: SFTBY) will reportedly invest $900 million into Pacific Biosciences of California Inc (NASDAQ: PACB), according to the Wall Street Journal, which comes on top of around 6% ...

Other stocks mentioned: SFTBY
2 months ago - Benzinga

Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.

2 months ago - Zacks Investment Research

On Wednesday, February 10, Pacific Biosciences (NASDAQ:PACB) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

2 months ago - Benzinga

MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of ge...

3 months ago - GlobeNewsWire

A new leadership team is betting that it can make long-read genome sequencing more competitive.

3 months ago - The Motley Fool

MENLO PARK, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of ge...

3 months ago - GlobeNewsWire

MENLO PARK, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financial results ...

3 months ago - GlobeNewsWire

After a large 13x rise since the March 23 levels of last year, at the current price of around $36 per share we believe Pacific Biosciences of California stock, a biotechnology company that develops gene...

3 months ago - Forbes

Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.

3 months ago - Zacks Investment Research

Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.

3 months ago - Zacks Investment Research

New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical care New platform expected to make whole genome sequencing significantly ...

3 months ago - GlobeNewsWire

MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read seque...

3 months ago - GlobeNewsWire

MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced una...

3 months ago - GlobeNewsWire

MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appointments of...

3 months ago - GlobeNewsWire

Seven new Sequel IIe Systems will support expanded generation of high-quality genomes for improving fundamental understanding of biology and aiding biodiversity conservation Seven new Sequel IIe Systems...

4 months ago - GlobeNewsWire

Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.

Other stocks mentioned: ABMD, MDRX
4 months ago - Zacks Investment Research

Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

MENLO PARK, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of ge...

4 months ago - GlobeNewsWire

BioCardia (NASDAQ: BCDA) shares are trading higher. The company said it anticipates data safety monitoring board verbal feedback by the end of Dec. 15 for its pivotal Phase 3 CardiAMP Heart Failure Trial.

Other stocks mentioned: HCA, BCDA
4 months ago - Benzinga

Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of its solid prospects.

5 months ago - Zacks Investment Research

About PACB

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonuclease... [Read more...]

Industry
Diagnostics & Research
IPO Date
Oct 27, 2010
Stock Exchange
NASDAQ
Ticker Symbol
PACB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for PACB stock is "Buy." The 12-month stock price forecast is 51.50, which is an increase of 106.91% from the latest price.

Price Target
$51.50
(106.91% upside)
Analyst Consensus: Buy